Alkermes Plc (ALKS) World Sleep Congress 2025 (Transcript)
Alkermes plc (NASDAQ:ALKS ) World Sleep Congress 2025 Conference September 8, 2025 8:00 AM EDT Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations R...
Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress...
– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily Dosing Across a Range of Doses – – ...
Alkermes: A More Than Solid Quarter
Alkermes plc is a mid-cap and quite profitable commercial-stage biopharma company, and we are revisiting it today for the first time in a year. The company just reported Q2 financial results, with ...
Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS ) Q2 2025 Earnings Call July 29, 2025 8:00 AM ET Company Participants Blair C. Jackson - Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO C.
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.
How Much Upside is Left in Alkermes (ALKS)? Wall Street Analysts Think 33.19%
The consensus price target hints at a 33.2% upside potential for Alkermes (ALKS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estim...
ALKS or CSLLY: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Alkermes (ALKS) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks ...
Alkermes plc (ALKS) Q4 2024 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS ) Q4 2024 Earnings Conference Call February 12, 2025 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs and Investor Relations Rich...
Here's Why Alkermes (ALKS) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680
Alkermes' (ALKS) phase II Vibrance-2 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with narcolepsy type 2.
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition
As we delve deeper into 2024, biotech stocks are commanding the attention of growth-focused investors. Despite facing volatility and regulatory challenges in recent years, biotech is poised for a r...
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.
Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street esti...
Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates
Alkermes (ALKS) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.01 per share a year ago.
Related Companies